Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial
ContributorsAl-Batran, Salah-Eddin; Homann, Nils; Pauligk, Claudia; Illerhaus, Gerald; Martens, Uwe M; Stoehlmacher, Jan; Schmalenberg, Harald; Luley, Kim B; Prasnikar, Nicole; Egger, Matthias; Probst, Stephan; Messmann, Helmut; Moehler, Markus; Fischbach, Wolfgang; Hartmann, Jörg T; Mayer, Frank; Höffkes, Heinz-Gert; Koenigsmann, Michael; Arnold, Dirk; Kraus, Thomas W; Grimm, Kersten; Berkhoff, Stefan; Post, Stefan; Jäger, Elke; Bechstein, Wolf; Ronellenfitsch, Ulrich; Moenig, Stefan Paul; Hofheinz, Ralf D
Published inJAMA oncology, vol. 3, no. 9, p. 1237-1244
Publication date2017-09-01
First online date2017-04-27
Abstract
Keywords
- Adenocarcinoma / drug therapy
- Adenocarcinoma / secondary
- Adenocarcinoma / surgery
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols / adverse effects
- Antineoplastic Combined Chemotherapy Protocols / therapeutic use
- Chemotherapy, Adjuvant
- Docetaxel
- Esophagogastric Junction
- Fluorouracil / administration & dosage
- Gastrectomy
- Humans
- Leucovorin / administration & dosage
- Liver Neoplasms / drug therapy
- Liver Neoplasms / secondary
- Liver Neoplasms / surgery
- Lung Neoplasms / drug therapy
- Lung Neoplasms / secondary
- Lung Neoplasms / surgery
- Lymphatic Metastasis
- Metastasectomy
- Middle Aged
- Neoadjuvant Therapy
- Neoplasm Staging
- Organoplatinum Compounds / administration & dosage
- Oxaliplatin
- Peritoneal Neoplasms / drug therapy
- Peritoneal Neoplasms / secondary
- Peritoneal Neoplasms / surgery
- Prospective Studies
- Stomach Neoplasms / drug therapy
- Stomach Neoplasms / pathology
- Stomach Neoplasms / surgery
- Survival Rate
- Taxoids / administration & dosage
- Young Adult
Affiliation entities Not a UNIGE publication
Citation (ISO format)
AL-BATRAN, Salah-Eddin et al. Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial. In: JAMA oncology, 2017, vol. 3, n° 9, p. 1237–1244. doi: 10.1001/jamaoncol.2017.0515
Main files (1)
Article (Published version)
Secondary files (2)
Identifiers
- PID : unige:158706
- DOI : 10.1001/jamaoncol.2017.0515
- PMID : 28448662
- PMCID : PMC5824287
Additional URL for this publicationhttps://jamanetwork.com/journals/jamaoncology/fullarticle/2621996
Journal ISSN2374-2437
